These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36055340)

  • 1. Bias correction based on weighted likelihood for conditional estimation of subgroup effects in randomized clinical trials.
    Toyoizumi K; Matsui S
    Stat Med; 2022 Nov; 41(26):5276-5289. PubMed ID: 36055340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker.
    Choai Y; Matsui S
    Biometrics; 2015 Mar; 71(1):25-32. PubMed ID: 25303178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reader reaction on estimation of treatment effects in all-comers randomized clinical trials with a predictive marker.
    Korn EL; Freidlin B
    Biometrics; 2017 Jun; 73(2):706-708. PubMed ID: 27775815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point estimation in adaptive enrichment designs.
    Kunzmann K; Benner L; Kieser M
    Stat Med; 2017 Nov; 36(25):3935-3947. PubMed ID: 28783881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inference on subgroups identified based on a heterogeneous treatment effect in a post hoc analysis of a clinical trial.
    Zhao B; Ivanova A; Fine J
    Clin Trials; 2023 Aug; 20(4):370-379. PubMed ID: 37170632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional estimation and inference to address observed covariate imbalance in randomized clinical trials.
    Zhang Z; Tang L; Liu C; Berger VW
    Clin Trials; 2019 Apr; 16(2):122-131. PubMed ID: 30444129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the optimal surrogate based on a randomized trial.
    Price BL; Gilbert PB; van der Laan MJ
    Biometrics; 2018 Dec; 74(4):1271-1281. PubMed ID: 29701875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the performance of Bayesian and restricted maximum likelihood estimation for stepped wedge cluster randomized trials with a small number of clusters.
    Grantham KL; Kasza J; Heritier S; Carlin JB; Forbes AB
    BMC Med Res Methodol; 2022 Apr; 22(1):112. PubMed ID: 35418034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A readily available improvement over method of moments for intra-cluster correlation estimation in the context of cluster randomized trials and fitting a GEE-type marginal model for binary outcomes.
    Westgate PM
    Clin Trials; 2019 Feb; 16(1):41-51. PubMed ID: 30295512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.
    Shimura M; Gosho M; Hirakawa A
    Stat Med; 2017 Jun; 36(13):2067-2080. PubMed ID: 28211076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design.
    Matsui S; Crowley J
    Clin Cancer Res; 2018 Mar; 24(5):994-1001. PubMed ID: 28887317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research.
    Wang H; Rosner GL; Goodman SN
    Clin Trials; 2016 Dec; 13(6):621-631. PubMed ID: 27271682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care.
    Aabenhus R; Jensen JU; Jørgensen KJ; Hróbjartsson A; Bjerrum L
    Cochrane Database Syst Rev; 2014 Nov; (11):CD010130. PubMed ID: 25374293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weighted nonparametric maximum likelihood estimate of a mixing distribution in nonrandomized clinical trials.
    Liu C; Xie J; Zhang Y
    Stat Med; 2007 Dec; 26(29):5303-19. PubMed ID: 17497612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the treatment effect following a clinical trial that stopped early for benefit.
    Marschner IC; Schou M; Martin AJ
    Stat Methods Med Res; 2022 Dec; 31(12):2456-2469. PubMed ID: 36065593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional maximum likelihood estimation in semiparametric transformation model with LTRC data.
    Chen CM; Shen PS
    Lifetime Data Anal; 2018 Apr; 24(2):250-272. PubMed ID: 28168333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical testing strategies for assessing treatment efficacy and marker accuracy in phase III trials.
    Nonaka T; Igeta M; Matsui S
    Pharm Stat; 2019 Jul; 18(4):459-475. PubMed ID: 30838777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional borrowing external data to establish a hybrid control arm in randomized clinical trials.
    Li H; Tiwari R; Li QH
    J Biopharm Stat; 2022 Nov; 32(6):954-968. PubMed ID: 35067183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct effect models.
    van der Laan MJ; Petersen ML
    Int J Biostat; 2008; 4(1):Article 23. PubMed ID: 22462121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.